You are hereDecember 10, 2018
What’s the Stem Cells Buzz this Week? - Stem Cell Mobilization, Skeletal Stem Cell Migration, Suicide System for Stem Cell Therapy, and Cystic Fibrosis Cell Therapy!
The Stem Cells Portal brings you a roundup of some of the new and exciting stories in the ever-changing world of stem cells, regenerative medicine, and beyond!
Chemotactic Tripeptide-Induced Mobilization of Angiogenic Stem Cells
A new study from the lab of Jae Ho Kim (Pusan National University School of Medicine, Yangsan, Republic of Korea) recently sought to understand how a collagen‐derived chemotactic tripeptide (Ac-PGP) mobilizes circulating angiogenic cells (CACs) from the bone marrow to contribute to the treatment of peripheral artery diseases. Employing a murine hindlimb ischemia model, Kwon et al. discovered that Ac-PGP stimulated blood perfusion and prevented limb amputation by promoting the mobilization of CACs through a CXCR2‐dependent mechanism. For more details on how this knowledge could lead to CAC‐mediated therapy for peripheral artery diseases, see STEM CELLS Translational Medicine now!
TAFA2 Neurokine Induces Skeletal Stem Cell Migration
Researchers from the lab of Abbas Jafari and Moustapha Kassem (University of Copenhagen, Denmark) hope to create a fuller understanding of the recruitment of human mesenchymal stem cells (hMSCs) to sites of tissue injury in order to develop more advanced regenerative therapies. In their new study, the team now demonstrate that the elevated expression of TAFA2, a recently discovered neurokine involved in neuronal cell migration and neurite outgrowth, at sites of skeletal fracture induces hMSC migration through activation of Rac1/p38 signaling. For more on the relevance of TAFA2 to regenerative medicine applications, see STEM CELLS now!
Suicide System in hiPSC-Neural Stem/Progenitor Therapy
The differentiation and transplantation of pluripotent derived cells carries a risk of tumorigenesis due to the presence of contaminating undifferentiated cells. Researchers from the labs of Hideyuki Okano and Masaya Nakamura (Keio University School of Medicine, Tokyo, Japan) recently introduced the herpes simplex virus type 1 thymidine kinase (HSVtk) gene into a human induced pluripotent stem cell‐derived neural stem/progenitor cell (hiPSC‐NS/PC) line known to undergo tumorigenic transformation. Encouragingly, the HSVtk system ablated all immature proliferating cells and permitted transplanted hiPSC‐NS/PC derivatives to safely return motor function to mice with injured spinal cords. Discover more at STEM CELLS Translational Medicine now!
Cell Therapy for Cystic Fibrosis Lung Disease
Previous studies from the lab of Susan D. Reynolds (Ohio State University, Columbus, Ohio, USA) that around 60 million human basal cells may be required to repopulate the human airway epithelium as a means to treat cystic fibrosis (CF) lung disease. The team now return with a new STEM CELLS Translational Medicine article in which they compare the proliferation potential of non‐CF and CF tissue‐derived bronchial basal cells. Overall, Hayes Jr. et al. demonstrate that non‐CF and CF basal cell proliferation is similar, CF basal cells can be amplified to a therapeutic cell dose, and amplified non‐CF and CF basal cell clones differentiate normally. However, cell amplification can deplete the regenerative basal cell pool. Overall, the authors hope that their findings will raise the possibility of cell therapy for CF.
That’s a wrap for now! Please feel free to leave a comment and discuss the papers covered here on the Stem Cells Buzz. Happy reading!